Tredje AP fonden Sells 5,441 Shares of Insulet Co. (NASDAQ:PODD)

Tredje AP fonden lessened its holdings in Insulet Co. (NASDAQ:PODD) by 50.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,442 shares of the medical instruments supplier’s stock after selling 5,441 shares during the period. Tredje AP fonden’s holdings in Insulet were worth $1,421,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Baillie Gifford & Co. grew its holdings in shares of Insulet by 3.5% during the fourth quarter. Baillie Gifford & Co. now owns 2,355,683 shares of the medical instruments supplier’s stock worth $614,998,000 after purchasing an additional 79,982 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Insulet by 1.3% during the third quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier’s stock worth $403,339,000 after purchasing an additional 22,850 shares during the last quarter. Westfield Capital Management Co. LP grew its holdings in shares of Insulet by 27.6% during the third quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock worth $175,697,000 after purchasing an additional 163,388 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Insulet by 1.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 646,959 shares of the medical instruments supplier’s stock worth $168,902,000 after purchasing an additional 10,694 shares during the last quarter. Finally, Fisher Asset Management LLC lifted its stake in shares of Insulet by 7.6% in the fourth quarter. Fisher Asset Management LLC now owns 377,694 shares of the medical instruments supplier’s stock worth $98,605,000 after acquiring an additional 26,594 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Piper Sandler lifted their price objective on Insulet from $285.00 to $310.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Wells Fargo & Company lifted their price objective on Insulet from $305.00 to $322.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Raymond James reaffirmed an “outperform” rating and issued a $328.00 price objective (up from $294.00) on shares of Insulet in a research note on Friday, February 21st. Stifel Nicolaus lifted their price objective on Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a research note on Friday, February 21st. Finally, Royal Bank of Canada initiated coverage on Insulet in a research note on Thursday, March 6th. They issued an “outperform” rating and a $340.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $292.06.

Insulet Trading Up 4.4 %

NASDAQ PODD opened at $255.44 on Friday. The company has a market cap of $17.94 billion, a price-to-earnings ratio of 44.12, a P/E/G ratio of 3.62 and a beta of 1.29. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $289.46. The business has a 50 day moving average price of $272.54 and a 200-day moving average price of $254.53. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The business had revenue of $597.50 million during the quarter, compared to the consensus estimate of $582.02 million. As a group, equities analysts expect that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the transaction, the executive vice president now owns 11,383 shares in the company, valued at $3,187,240. This represents a 52.13 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.47% of the stock is currently owned by corporate insiders.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.